As of January–October 2025, the retail market for locally acting nasal disease treatments (group R01A) reached 53.8 billion rubles (in retail prices, including VAT). Total consumer spending within the category increased by 8.3 percent compared to the same period in 2024. Over ten months, Russians purchased 296.6 million packages of such products; year-on-year, physical consumption in the group rose by 2.3 percent. Notably, over the past three years, unit-based demand has grown only slightly, while the value dynamics of sales have shown double-digit growth for the past two years.

It is important to note that this therapeutic group is the most in-demand on the Russian retail pharmaceutical market in terms of physical consumption. Demand for nasal disease treatments follows a clear seasonal pattern, with sales typically increasing during the autumn–winter period or in spring; in the current year, such increases were recorded in March and September. In each of these months, Russians purchased more than 36 million packages of relevant products totaling 6.5 billion rubles. In October, demand for nasal remedies declined slightly compared to the previous month (–7 percent in rubles versus September). Remarkably, this pattern repeats annually: after the September spike, demand decreases through late autumn, rising again in December.

According to the “Retail Sales Audit of Medicinal Products in Russia (total sell out)” database by the analytical company RNC Pharma, decongestants account for the majority of unit sales—around 87 percent during the reporting period, with their share in value terms exceeding 60 percent. In total, as of the first ten months of 2025, the retail segment (including the online channel) featured over 130 nasal disease treatment brands produced by 106 corporations.

In the ranking table, Otrivin (Helion) moved to first place. The product accounts for 9.3 percent of all monetary spending in the category; compared with January–October 2024, the brand showed growth of +25 percent in rubles and +23 percent in packages. Notably, sales increased across all SKUs, both in value and volume. Snoop (Nizhpharm) fell to second place with a 7.9 percent share. Compared to January–October 2024, demand for this product declined by 12 percent in units, and monetary spending fell by 8 percent. Rhinonorm (Teva) occupies third place, having risen two positions; during the reporting period, the product accounted for 6.8 percent of value sales in the group with growth of +24 percent in rubles. Moreover, the brand showed the second-highest value growth rate within the top ten, just slightly behind the leader. Also noteworthy in the ranking are Tizin (Johnson & Johnson, +18 percent in rubles) and Naphthyzin (manufactured by 19 companies), which demonstrated an overall value growth of 15 percent.

Outside the top ten, notable performers include Glenmark’s Ryaltris, which showed value growth of +49 percent versus January–October 2024, and Morelor (Yuzhpharm, +45 percent). In addition, demand has been steadily rising for Sinusefrin (Tula Pharm Factory) for the third consecutive year (+36 percent).

Table. Top 10 brands of locally acting nasal disease treatments (group R01A under the EphMRA classification), by value sales on the Russian retail pharmaceutical market in January–October 2025